Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX005425 in MSI-H/dMMR Advanced Solid Tumors
NCT07208136Phase 1Recruiting
- Sponsor
- Jemincare
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JMKX005425 in solid tumor (advanced stage), sponsored by Jemincare. Primary endpoint: Number of participants with dose limiting toxicities (DLTs), Adverse Events (AEs), Serious Adverse Events (SAEs) up to 2 years. Started Oct 2025; status: recruiting.
02
Drugs
JMKX005425
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07208136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208136.